CBR1通过调节细胞干性和静止状态介导非小细胞肺癌化疗敏感性

李伟文; 赵嘉璐; 蓝伟红; 叶肖菲; 应可净

doi:10.1631/jzus.B2400509

Your Location：

Home >

Browse articles >

CBR1通过调节细胞干性和静止状态介导非小细胞肺癌化疗敏感性

Scan QR Code

文章被引用时，请邮件提醒。

Submit

Research Article | Updated：2025-12-31

CBR1通过调节细胞干性和静止状态介导非小细胞肺癌化疗敏感性
Depleting CBR1 increases chemosensitivity by reducing stemness and quiescence traits in non-small cell lung cancer
浙江大学学报（英文版）（B辑：生物医学和生物技术） 2025年26卷第12期页码：1216-1232
Affiliations：

1.Department of Respiratory and Critical Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
2.Department of Respiratory and Critical Medicine, The Fifth Affiliated Hospital to Wenzhou Medical University, Lishui 323000, China
Funds：

the National Natural Science Foundation of China(82170054);the Natural Science Foundation of Zhejiang Province(Y21H010014)
DOI：10.1631/jzus.B2400509
中图分类号：
CSTR：
收稿：2024-10-14，

修回：2025-01-06，

网络出版：2025-12-17，

纸质出版：2025-12-31
Accepted：

李伟文,赵嘉璐,蓝伟红等.CBR1通过调节细胞干性和静止状态介导非小细胞肺癌化疗敏感性[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2025,26(12):1216-1232.

Weiwen LI, Jialu ZHAO, Weihong LAN, et al. Depleting CBR1 increases chemosensitivity by reducing stemness and quiescence traits in non-small cell lung cancer[J]. Journal of Zhejiang University-SCIENCE B, 2025, 26(12): 1216-1232.
李伟文,赵嘉璐,蓝伟红等.CBR1通过调节细胞干性和静止状态介导非小细胞肺癌化疗敏感性[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2025,26(12):1216-1232. DOI： 10.1631/jzus.B2400509.

Weiwen LI, Jialu ZHAO, Weihong LAN, et al. Depleting CBR1 increases chemosensitivity by reducing stemness and quiescence traits in non-small cell lung cancer[J]. Journal of Zhejiang University-SCIENCE B, 2025, 26(12): 1216-1232. DOI： 10.1631/jzus.B2400509.

摘要

羰基还原酶1（CBR1）作为短链脱氢酶/还原酶（SDR）超家族一员，与肿瘤进展和治疗抵抗有关，但其在非小细胞肺癌（NSCLC）中的具体作用尚不明确。本研究检测了CBR1在NSCLC组织和细胞系中的表达，采用基因干扰和药物抑制方法，评估了CBR1对肿瘤干性、化疗敏感性和细胞静止状态的影响，进一步探讨了其潜在机制。研究结果表明，CBR1在NSCLC组织和细胞系中表达升高，且顺铂（CDDP）处理可进一步诱导其表达上调。通过基因干扰下调CBR1表达后，CD133阳性细胞百分比显著降低，OCT4和SOX2的表达下降，同时细胞对CDDP的化疗敏感性增强。CBR1特异性抑制剂hydroxy-PP-Me（PP-Me）显著增加了CDDP的细胞毒性，并抑制了细胞干性。此外，sh-CBR1或PP-Me处理能够有效改变NSCLC细胞的静止状态，具体表现为G0期细胞比例和p27表达下降而cyclin D1和pRb表达上升。进一步研究发现，SETD4作为介导NSCLC细胞干性、化疗敏感性和静止状态的因子，在sh-CBR1或PP-Me处理后表达下调而过表达SETD4则可逆转由CBR1抑制所增强的化疗敏感性。在A549异种移植模型中，PP-Me与CDDP联合治疗的抑瘤效果显著优于单药治疗。综上所述，抑制CBR1可通过阻断肿瘤干性与静止期，增强NSCLC对CDDP的化疗敏感性。

Abstract

Carbonyl reductase 1 (CBR1)

a member of the short-chain dehydrogenase/reductase (SDR) superfamily

is implicated in tumor progression and treatment resistance. However

its role in non-small cell lung cancer (NSCLC) remains unclear. This study examined CBR1 expression in NSCLC tissues and cell lines

using gene interference and pharmacological inhibition to assess its impact on stemness

chemosensitivity

and quiescence

and to explore underlying mechanisms. Our findings indicate that CBR1 expression is elevated in NSCLC tissues and cell lines

and further increases in the presence of cisplatin (CDDP). Gene interference reducing CBR1 expression significantly decreased the percentage of cluster of differentiation 133 (CD133)-positive cells and the expression of octamer-binding transcription factor 4 (OCT4) and SRY (sex determining region Y)-box 2 (SOX2)

while enhancing CDDP chemosensitivity. The CBR1-specific inhibitor hydroxy-PP-Me (PP-Me) markedly increased CDDP cytotoxicity and reduced stemness. Additionally

CBR1 inhibition via short hairpin RNA (shRNA) CBR1 (sh-CBR1) or PP-Me disrupted NSCLC cell quiescence

as shown by a decrease in G0 phase cells and p27 expression

alongside an increase in cyclin D1 and phospho-retinoblastoma (pRb) expression. Furthermore

SET domain-containing protein 4 (SETD4)

which mediates stemness

chemosensitivity

and quiescence in NSCLC cells

was downregulated by sh-CBR1 or PP-Me treatment. The overexpression of SETD4 counteracted the enhanced chemosensitivity resulting from CBR1 inhibition. In A549 xenografts

combined PP-Me and CDDP therapy significantly inhibited tumor growth compared to either treatment alone. In conclusion

CBR1 inhibition enhances CDDP chemosensitivity by suppressing stemness and quiescence in NSCLC.

关键词

Keywords

references

Bray JE , Marsden BD , Oppermann U , 2009 . The human short-chain dehydrogenase/reductase (SDR) superfamily: a bioinformatics summary . Chem Biol Interact , 178 ( 1-3 ): 99 - 109 . https://doi.org/10.1016/j.cbi.2008.10.058 https://doi.org/10.1016/j.cbi.2008.10.058

Brody H , 2020 . Lung cancer . Nature , 587 ( 7834 ): S7 . https://doi.org/10.1038/d41586-020-03152-0 https://doi.org/10.1038/d41586-020-03152-0

Cai SL , Yang YS , Ding YF , et al. , 2022 . SETD4 cells contribute to brain development and maintain adult stem cell reservoir for neurogenesis . Stem Cell Reports , 17 ( 9 ): 2081 - 2096 . https://doi.org/10.1016/j.stemcr.2022.07.017 https://doi.org/10.1016/j.stemcr.2022.07.017

Chen G , Zhang HH , Sun HX , et al. , 2023a . Bufalin targeting BFAR inhibits the occurrence and metastasis of gastric cancer through PI3K/AKT/mTOR signal pathway . Apoptosis , 28 ( 9-10 ): 1390 - 1405 . https://doi.org/10.1007/s10495-023-01855-z https://doi.org/10.1007/s10495-023-01855-z

Chen G , Yang LN , Liu GX , et al. , 2023b . Research progress in protein microarrays: focussing on cancer research . Proteom Clin Appl , 17 ( 1 ): 2200036 . https://doi.org/10.1002/prca.202200036 https://doi.org/10.1002/prca.202200036

Chen KC , Zhang CZ , Ling SB , et al. , 2021 . The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance . Cell Death Discov , 12 ( 9 ): 835 . https://doi.org/10.1038/s41419-021-04116-6 https://doi.org/10.1038/s41419-021-04116-6

Dai L , Ye S , Li HW , et al. , 2017 . SETD4 regulates cell quiescence and catalyzes the trimethylation of H4K20 during diapause formation in Artemia . Mol Cell Biol , 37 ( 7 ): e00453-16 . https://doi.org/10.1128/MCB.00453-16 https://doi.org/10.1128/MCB.00453-16

Galluzzi L , Senovilla L , Vitale I , et al. , 2012 . Molecular mechanisms of cisplatin resistance . Oncogene , 31 ( 15 ): 1869 - 1883 . https://doi.org/10.1038/onc.2011.384 https://doi.org/10.1038/onc.2011.384

Heng WS , Gosens R , Kruyt FAE , 2019 . Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting . Biochem Pharmacol , 160 : 121 - 133 . https://doi.org/10.1016/j.bcp.2018.12.010 https://doi.org/10.1016/j.bcp.2018.12.010

Herz HM , Garruss A , Shilatifard A , 2013 . SET for life: biochemical activities and biological functions of SET domain-containing proteins . Trends Biochem Sci , 38 ( 12 ): 621 - 639 . https://doi.org/10.1016/j.tibs.2013.09.004 https://doi.org/10.1016/j.tibs.2013.09.004

Iwamoto Y , Mitsudomi T , Sakai K , et al. , 2015 . Randomized phase II study of adjuvant chemotherapy with long-term S-1 versus cisplatin+S-1 in completely resected stage II-IIIA non-small cell lung cancer . Clin Cancer Res , 21 ( 23 ): 5245 - 5252 . https://doi.org/10.1158/1078-0432.CCR-14-3160 https://doi.org/10.1158/1078-0432.CCR-14-3160

Jang M , Kim Y , Won H , et al. , 2012 . Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide . Cancer Res , 72 ( 16 ): 4214 - 4224 . https://doi.org/10.1158/0008-5472.CAN-12-1110 https://doi.org/10.1158/0008-5472.CAN-12-1110

Jiang X , Li Y , Feng JL , et al. , 2020 . Safrana l prevents prostate cancer recurrence by blocking the re-activation of quiescent cancer cells via downregulation of S-phase kinase-associated protein 2 . Front Cell Dev Biol , 8 : 598620 . https://doi.org/10.3389/fcell.2020.598620 https://doi.org/10.3389/fcell.2020.598620

Jo A , Choi TG , Jo YH , et al. , 2017 . Inhibition of carbonyl reductase 1 safely improves the efficacy of doxorubicin in breast cancer treatment . Antioxid Redox Sign , 26 ( 2 ): 70 - 83 . https://doi.org/10.1089/ars.2015.6457 https://doi.org/10.1089/ars.2015.6457

Kalabus JL , Cheng QY , Jamil RG , et al. , 2012 . Induction of carbonyl reductase 1 ( CBR1 ) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[ a ] pyrene . Toxicol Lett , 211 ( 3 ): 266 - 273 . https://doi.org/10.1016/j.toxlet.2012.04.006 https://doi.org/10.1016/j.toxlet.2012.04.006

Kavanagh KL , Jörnvall H , Persson B , et al. , 2008 . Medium- and short-chain dehydrogenase/reductase gene and protein families: the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes . Cell Mol Life Sci , 65 ( 24 ): 3895 . https://doi.org/10.1007/s00018-008-8588-y https://doi.org/10.1007/s00018-008-8588-y

Koczurkiewicz-Adamczyk P , Piska K , Gunia-Krzyżak A , et al. , 2020 . Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells ‒ involvement of carbonyl reductase 1 . Eur J Pharm Sci , 154 : 105511 . https://doi.org/10.1016/j.ejps.2020.105511 https://doi.org/10.1016/j.ejps.2020.105511

Koczurkiewicz-Adamczyk P , Gąsiorkiewicz B , Piska K , et al. , 2022 . Cinnamamide derivatives with 4-hydroxypiperidine moiety enhance effect of doxorubicin to cancer cells and protect cardiomyocytes against drug-induced toxicity through CBR1 inhibition mechanism . Life Sci , 305 : 120777 . https://doi.org/10.1016/j.lfs.2022.120777 https://doi.org/10.1016/j.lfs.2022.120777

Lal S , Sandanaraj E , Wong ZW , et al. , 2008 . CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients . Cancer Sci , 99 ( 10 ): 2045 - 2054 . https://doi.org/10.1111/j.1349-7006.2008.00903.x https://doi.org/10.1111/j.1349-7006.2008.00903.x

Liao XM , Wu CX , Shao ZM , et al. , 2021 . SETD4 in the proliferation, migration, angiogenesis, myogenic differentiation and genomic methylation of bone marrow mesenchymal stem cells . Stem Cell Rev Rep , 17 ( 4 ): 1374 - 1389 . https://doi.org/10.1007/s12015-021-10121-1 https://doi.org/10.1007/s12015-021-10121-1

Massey AJ , Benwell K , Burbridge M , et al. , 2021 . Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma . J Cell Mol Med , 25 ( 22 ): 10650 - 10662 . https://doi.org/10.1111/jcmm.17002 https://doi.org/10.1111/jcmm.17002

Matsunaga T , Kezuka C , Morikawa Y , et al. , 2015 . Up-regulation of carbonyl reductase 1 renders development of doxorubicin resistance in human gastrointestinal cancers . Biol Pharm Bull , 38 ( 9 ): 1309 - 1319 . https://doi.org/10.1248/bpb.b15-00176 https://doi.org/10.1248/bpb.b15-00176

Miller M , Hanna N , 2021 . Advances in systemic therapy for non-small cell lung cancer . BMJ , 375 : n2363 . https://doi.org/10.1136/bmj.n2363 https://doi.org/10.1136/bmj.n2363

Morin-Buote J , Ennour-Idrissi K , Poirier É , et al. , 2021 . Association of breast tumour expression of cannabinoid receptors CBR1 and CBR2 with prognostic factors and survival in breast cancer patients . J Pers Med , 11 ( 9 ): 852 . https://doi.org/10.3390/jpm11090852 https://doi.org/10.3390/jpm11090852

Mukhopadhyay D , Goel HL , Xiong CA , et al. , 2023 . The calcium channel TRPC6 promotes chemotherapy-induced persistence by regulating integrin α6 mRNA splicing . Cell Rep , 42 ( 11 ): 113347 . https://doi.org/10.1016/j.celrep.2023.113347 https://doi.org/10.1016/j.celrep.2023.113347

Murakami A , Yakabe K , Yoshidomi K , et al. , 2012 . Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance . Cancer Lett , 323 ( 1 ): 69 - 76 . https://doi.org/10.1016/j.canlet.2012.03.035 https://doi.org/10.1016/j.canlet.2012.03.035

Niho S , Yoshida T , Akimoto T , et al. , 2020 . Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study . Lung Cancer , 141 : 64 - 71 . https://doi.org/10.1016/j.lungcan.2020.01.008 https://doi.org/10.1016/j.lungcan.2020.01.008

Oppermann U , 2007 . Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology . Annu Rev Pharmacol Toxicol , 47 ( 1 ): 293 - 322 . https://doi.org/10.1146/annurev.pharmtox.47.120505.105316 https://doi.org/10.1146/annurev.pharmtox.47.120505.105316

Osawa Y , Yokoyama Y , Shigeto T , et al. , 2015 . Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation . Int J Oncol , 46 ( 3 ): 1252 - 1258 . https://doi.org/10.3892/ijo.2014.2810 https://doi.org/10.3892/ijo.2014.2810

Pennycook BR , Barr AR , 2020 . Restriction point regulation at the crossroads between quiescence and cell proliferation . FEBS Lett , 594 ( 13 ): 2046 - 2060 . https://doi.org/10.1002/1873-3468.13867 https://doi.org/10.1002/1873-3468.13867

Piska K , Koczurkiewicz P , Wnuk D , et al. , 2019 . Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells ‒ the involvement of carbonyl reductase 1 inhibition . Chem Biol Interact , 300 : 40 - 48 . https://doi.org/10.1016/j.cbi.2019.01.003 https://doi.org/10.1016/j.cbi.2019.01.003

Schlager JJ , Powis G , 1990 . Cytosolic NAD(P)H:(Quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol . Int J Cancer , 45 ( 3 ): 403 - 409 . https://doi.org/10.1002/ijc.2910450304 https://doi.org/10.1002/ijc.2910450304

Shi SM , Di L , 2017 . The role of carbonyl reductase 1 in drug discovery and development . Expert Opin Drug Metab Toxicol , 13 ( 8 ): 859 - 870 . https://doi.org/10.1080/17425255.2017.1356820 https://doi.org/10.1080/17425255.2017.1356820

Siegel RL , Miller KD , Fuchs HE , et al. , 2021 . Cancer statistics, 2021 . CA A Cancer J Clin , 71 ( 1 ): 7 - 33 . https://doi.org/10.3322/caac.21654 https://doi.org/10.3322/caac.21654

Tak E , Lee S , Lee J , et al. , 2011 . Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells . J Hepatol , 54 ( 2 ): 328 - 339 . https://doi.org/10.1016/j.jhep.2010.06.045 https://doi.org/10.1016/j.jhep.2010.06.045

Wang YH , Yu YM , Yang WJ , et al. , 2023 . SETD4 confers cancer stem cell chemoresistance in nonsmall cell lung cancer patients via the epigenetic regulation of cellular quiescence . Stem Cells Int , 2023 : 7367854 . https://doi.org/10.1155/2023/7367854 https://doi.org/10.1155/2023/7367854

Ye S , Ding YF , Jia WH , et al. , 2019 . SET domain-containing protein 4 epigenetically controls breast cancer stem cell quiescence . Cancer Res , 79 ( 18 ): 4729 - 4743 . https://doi.org/10.1158/0008-5472.CAN-19-1084 https://doi.org/10.1158/0008-5472.CAN-19-1084

Zhang HH , Zhang Z , Guo TT , et al. , 2023a . Annexin A protein family: focusing on the occurrence, progression and treatment of cancer . Front Cell Dev Biol , 11 : 1141331 . https://doi.org/10.3389/fcell.2023.1141331 https://doi.org/10.3389/fcell.2023.1141331

Zhang HH , Dong XL , Ding XY , et al. , 2023b . Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway . J Transl Med , 21 : 900 . https://doi.org/10.1186/s12967-023-04613-6 https://doi.org/10.1186/s12967-023-04613-6

Zhang YJ , Zhang HX , Zhang XL , et al. , 2022 . CBR3-AS1 accelerates the malignant proliferation of gestational choriocarcinoma cells by stabilizing SETD4 . Dis Markers , 2022 : 7155525 . https://doi.org/10.1155/2022/7155525 https://doi.org/10.1155/2022/7155525

Zhong YY , Ye P , Mei ZZ , et al. , 2019 . The novel methyltransferase SETD4 regulates TLR agonist-induced expression of cytokines through methylation of lysine 4 at histone 3 in macrophages . Mol Immunol , 114 : 179 - 188 . https://doi.org/10.1016/j.molimm.2019.07.011 https://doi.org/10.1016/j.molimm.2019.07.011

Zhou L , Yang C , Zhong WL , et al. , 2021 . Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells . Biochem Pharmacol , 193 : 114813 . https://doi.org/10.1016/j.bcp.2021.114813 https://doi.org/10.1016/j.bcp.2021.114813

Zhu SX , Xu YP , Song M , et al. , 2016 . PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening . Mol Med Rep , 14 ( 4 ): 3357 - 3361 . https://doi.org/10.3892/mmr.2016.5605 https://doi.org/10.3892/mmr.2016.5605

浏览量

Downloads

CSCD

工具集

关联资源

Chronic exposure to hexavalent chromium induces esophageal tumorigenesis via activating the Notch signaling pathway

FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1

Multiple characteristic alterations and available therapeutic strategies of cellular senescence